The role of enhanced external counter pulsation therapy in clinical practice.
Clin Med Res
; 11(4): 226-32, 2013 Dec.
Article
in En
| MEDLINE
| ID: mdl-24510321
ABSTRACT
Enhanced external counterpulsation (EECP) has been approved by the United States Food and Drug Administration (FDA) for management of refractory angina (Class IIb). EECP uses three sets of pneumatic cuffs that sequentially contract during diastole, increasing aortic diastolic pressure, augmenting coronary blood flow and central venous return. EECP improves anginal symptoms and exercise tolerance, and reduces nitroglycerin use in patients with chronic, stable angina. EECP has also been shown to be safe and beneficial in patients with symptomatic stable congestive heart failure. It has been postulated that cardiac benefits of EECP are mediated though vascular endothelial growth factor (VEGF) and nitric oxide mediated vasodilatation and angiogenesis. In June 2002, the FDA also approved EECP therapy for heart failure patients.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Counterpulsation
/
Angina Pectoris
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Clin Med Res
Year:
2013
Type:
Article